Will Pfizer (PFE) Stock Be Affected by Pneumonia Vaccine Approval?

The FDA approved Pfizer’s (PFE) pneumonia vaccine for infants and younger adults.
By Rachel Aldrich ,

NEW YORK (TheStreet) -- Pfizer (PFE) - Get Report  announced today that the FDA approved its pneumonia vaccine, Prevnar, MarketWatch reports.

Prevnar is meant to protect against 13 different strains of bacteria that cause pneumonia and other diseases.

With the new approval, the vaccine can now be administered to infants, young children and to adults aged 18 to 49.

The vaccine had previously been approved for children aged 6 to 17 years and for adults over the age of 50. It's already included in immunization programs in 102 countries.

Shares of Pfizer closed up 0.25% to $36.24 today.

(Pfizer is held in the Dividend Stock Adviser Profile. To see all of the holdings, click here.)

Separately, TheStreet Ratings rated this stock as a "buy" with a ratings score of A-.

The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and good cash flow from operations. TheStreet Ratings feels its strengths outweigh the fact that the company has had somewhat disappointing return on equity.

You can view the full analysis from the report here: PFE

Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. 

Loading ...